Abstract 386P
Background
Wnt/β-catenin pathway is closely related to the development and progression of laryngeal squamous cell carcinoma (LSCC). Loss or reduction of ubiquitination and degradation of β-catenin in cytoplasm result in its accumulation in the nucleus and over-activation of the Wnt/β-catenin pathway. Folate receptor 1 (FRα) is overexpressed in numerous epithelial malignancies. However, the effect of FRα on Wnt/β-catenin pathway and its role in LSCC remains unclear.
Methods
Real-time RT-PCR, Western blot and immunohistochemistry(IHC) detects the mRNA and protein level of FRα in 30 cases of laryngeal squamous cell carcinoma (LSCC) tissues and adjacent normal tissues; Flag-FRα and Si# FRα plasmids were constructed and transfected to establish high FRα expression and low FRα expression cells; EdU assay, colony formation, scratch assay and transwell assay were performed to detect the of proliferation, colony formation, migration and invasion ability of cells; SiRNA#β-catenin was used to block Wnt/β-catenin signal and detected the ability of proliferation, colony formation, migration and invasion; confocal laser detects the subcellular distribution of β-catenin; SgRNA#EGFR was used to silence EGFR signal ; co-immunoprecipitation detects the ubiquitination level of β-catenin.
Results
Q-RT-PCR, WB and IHC showed that the mRNA and protein level of FRα in laryngeal carcinoma tissues was significantly higher than adjacent tissues, and the difference was statistically significant (P<0.01). Compared with FRα low expression (TU177/Flag and TU212/Si-FRα) cells, the proliferation, colony formation, migration and invasion abilities of FRα high expression (TU177/Flag-FRα and TU212/Si-NC) cells were enhanced; SiRNA#β-catenin inhibited FRα -induced cell proliferation, colony formation and migration. Confocal laser results showed that the nuclear accumulation of β-catenin was increased in FRα high expression cells. SgRNA#EGFR inhibited FRα -induced nuclear translocation of β-catenin. Co-immunoprecipitation results displayed that the ubiquitination of β-catenin was decreased in FRα high expression cells.
Conclusions
FOLR1 stabilized β-catenin promotes laryngeal carcinoma progression through EGFR signa.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
H.Tuo.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
123P - Spatial molecular profiling identifies FGF20 upregulation on cancer-associated fibroblast and FGFR2-PI3K/Akt activation in tumor cells of sporadic early-onset colon cancer
Presenter: Dave Hoon
Session: Poster Display
Resources:
Abstract
124P - Characteristics, prognosis and therapeutic effects of non-V600 BRAF mutated colorectal cancer
Presenter: Lalida Arsa
Session: Poster Display
Resources:
Abstract
125P - Final results of APOLLON-11 and SOYUZ-APOLLON study: Multicentre prospective observational post-authorization study of bevacizumab biosimilar in patients with metastatic colorectal cancer in real-world practice
Presenter: Alexey Tryakin
Session: Poster Display
Resources:
Abstract
126P - From tumor height (TH) to tumor regression grade (TRG) in locally advanced rectal cancers (LARC) during total neadjuvant therapy (TNT): A retrospective analysis
Presenter: Valeria Pusceddu
Session: Poster Display
Resources:
Abstract
127P - A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness
Presenter: Takayuki Yoshino
Session: Poster Display
Resources:
Abstract
128TiP - A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
140P - Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
Presenter: Hoo Hwoei Fen Soo
Session: Poster Display
Resources:
Abstract
141P - Early phase trials outcomes in refractory upper GI cancers: A 10-year analysis from the SCRI UK phase I unit
Presenter: Antonella Cammarota
Session: Poster Display
Resources:
Abstract
142P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract